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Available online 21 March 2016Background:Host genetic factors of interleukin (IL)-1 polymorphisms inﬂuenceHelicobacter pylori infection path-
ogenic activity. We examined whether H. pylori-infected patients with IL-1 polymorphisms are associated with
myocardial infarction (MI).
Materials and methods:We recruited 594 consecutive coronary artery disease patients and excluded those who
met exclusion criteria. Aftermatching age and sex, 82 caseswithMI and 82 controlswere enrolled. Immunoglob-
ulin G antibodies against H. pylori and IL-1 polymorphisms (IL-1 beta-511 base pairs and IL-1 receptor antago-
nist) were analyzed. We assessed high sensitivity C-reactive protein (hs-CRP) level and reactive hyperemia-
peripheral arterial tonometry (RH-PAT) index (RHI) using the EndoPAT2000 system.
Results: The simultaneous prevalence of H. pylori-seropositivity and IL-1 polymorphisms was 45.1% and 19.5% in
the cases and controls, respectively (P=0.001).H. pylori-positive patients with IL-1 polymorphisms showed sig-
niﬁcantly higher serum levels of natural logarithm of hs-CRP in the cases and controls (−2.8 ± 1.0 vs.−3.4 ±
0.6, respectively; P= 0.003 and−2.8± 0.9 vs.−3.2± 0.6, respectively; P= 0.02) and signiﬁcantly lower levels
of natural logarithm of RHI in the cases and controls (0.51 ± 0.13 vs. 0.61 ± 0.23, respectively; P = 0.039 and
0.47 ± 0.13 vs. 0.69 ± 0.23, respectively; P = 0.005). H. pylori-seropositivity with IL-1 polymorphisms was sig-
niﬁcantly associated withMI by logistic regression analysis (odds ratio, 4.83; 95% conﬁdence interval, 1.99–11.7;
P b 0.001).
Conclusions: H. pylori-positive patientswith IL-1 polymorphisms showed higher levels of hs-CRP and lower levels
of RHI, and were signiﬁcantly correlated with the MI.







Chronic bacterial infections have been suggested to be associated
with the risk of myocardial infarction (MI) [1,2]. Helicobacter pylori
(H. pylori) is the most common chronic bacterial infection in
humans, and it has been demonstrated worldwide and in individuals
of all ages. Previous studies have shown an association between000016482; URL: http://www.
arMedicine, Graduate School of
Chuo-ku, Kumamoto City 860-
moto).
. This is an open access article underH. pylori andMI, [3] but other studies have not demonstrated such an as-
sociation [4].
The pro-inﬂammatory cytokine, interleukin (IL)-1 beta, inﬂuences
the clinical outcomes of an H. pylori infection [5]. The IL-1 beta gene
has three diallelic polymorphisms at positions −511, −31, and
+3954 base pairs (bp) from the transcriptional start site, [6] even
though there are conﬂicting data regarding the functional effects of
these polymorphisms on IL-1-beta production [7,8]. The gene for the
IL-1 receptor antagonist (IL-1RN) has a variable number of identical tan-
dem repeats of 86 bp in length in intron 2, and the less common allele 2
(IL-1RN*2) is associated with awide range of chronic inﬂammatory and
autoimmune conditions [6]. A previous study reported that carriage of
the IL-1 beta-511 genotype or IL-1RN *2 allele was signiﬁcantly associ-
ated with H. pylori-related gastric mucosal IL-1 beta levels and the inci-
dence of gastric cancer [9].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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polymorphisms, and host genetic factors that affect inﬂammation may
explain why some individuals infected with H. pylori develop MI, while
others do not. In this study, we examined the association of H. pylori in-
fection and IL-1 polymorphisms with MI.
2. Methods
2.1. Study population
Patients were recruited between January 2009 and December 2012.
The case subjectswerepatientswithMIwhohadbeen admitted toKuma-
moto University Hospital. Kumamoto University Hospital is located in the
Kumamoto Prefecture southwest of Tokyo and has a population of ap-
proximately 1.8 million people. MI included ST-elevation MI and non-
ST-elevationMI, andweused theuniversal deﬁnition ofMI [10]. Case sub-
jects started with consecutive 594 coronary artery disease and patients
with stable coronary artery disease (n = 344), serum sample deﬁciency
(n=93), unstable angina pectoris (n=43), and patientswithmalignan-
cy (n= 8), hypoxia (n= 2), other inﬂammatory diseases (n= 6), colla-
gen disease (n=2) and hemodialysis (n=1)were excluded. As a result,
95MI patients were analyzed. There are generallymany elderly people in
patients with coronary artery disease, so control subjects included indi-
viduals aged N60 years undergoing medical examination or treatment
at our hospital. We enrolled consecutive individuals who did not have a
history of atherosclerotic diseases such as coronary artery disease, stroke,
or peripheral arterial disease and as a result, 95 patients without athero-
sclerotic diseases agreed with participation in this study. After matching
age and sex, 82 cases and 82 controls were enrolled (Fig. 1).
The study compliedwith the Declaration of Helsinki, and the human
ethics committee of Kumamoto University approved it. The ﬁle number
and year for the Ethics Committee approval is 64 and January 16 2003.
Written informed consent was obtained from all the patients.
2.2. Laboratory methods
The cases and controls provided venous blood samples, which were
centrifuged, and the serum was stored at−80 °C until analysis. Immu-
noglobulin G (IgG) antibodies against H. pylori were measured using aFig. 1. Flow chart showing the protocol used for endirect enzyme-linked immunosorbent assay kit (E Plate Eiken H. pylori
Antibody, Eiken Chemical Co., Ltd., Tokyo, Japan). Levels of IgGwere cat-
egorized as seropositive and seronegative forH. pylori according to a se-
lective cutoff value (492 nm). Using the same kit, it was reported that
the sensitivity and speciﬁcity of the kit with respect to cell culture and
rapid urease test in 70 Japanese subjects were 100% and 80.0%,
respectively [11]. The measurements of high sensitivity C-reactive pro-
tein (hs-CRP) level were performed in the laboratory of our hospital
using routine enzymatic methods. Since acute phase proteins such
as hs-CRP are up-regulated in acute MI patients, we collected data of
hs-CRP 6–9 months after admission for acute MI as far as possible,
though medications such as statins subscribed on the admission might
inﬂuence the CRP levels.
2.3. Genotyping
DNA was extracted from whole blood using the DNA extractor WB
kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan) by following
themodiﬁed protocol described by Richards et al. [12]. A single bp poly-
morphism at−511 in the promoter region of the IL-1 beta (rs16944)
was determined using a real-time TaqMan allelic discrimination assay
(Step One Plus Real-Time PCR system, version 2.1; Applied Biosystems,
Tokyo, Japan) according to the protocols provided by the manufacturer
(assay no.: C_1839943_10). All the reagents were purchased from Ap-
plied Biosystems. It was reported that within the IL-1 beta gene, the T
and C alleles at the−511 locuswere in near total linkage disequilibrium
with the C and T alleles at the−31 locus [13], and the frequency of an-
other polymorphism at position+3954 is very rare in Japanese popula-
tions, [14] so we restricted the analysis to the IL-1 beta-511 locus. The
IL-1RN polymorphism was based on the number of an 86 bp repeat,
and the analysis of the IL-1RN polymorphism was performed using po-
lymerase chain reaction (PCR) as described previously. [15] In this
study, we deﬁned IL-1 polymorphisms as the carriage of either IL-1
beta-511 T allele or IL-1RN *2 allele.
2.4. Assessment of endothelial function
A previous report suggested that inﬂammation and CRP might
directly contribute to endothelial dysfunction [16]. Peripheralrolling the patients. MI, myocardial infarction.
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terial tonometry (RH-PAT) using the EndoPAT2000 system (Itamar
Medical, Caesarea, Israel), as described previously [17]. Previous studies
have demonstrated that RH-PAT has excellent reproducibility [18]. We
measured RH-PAT index (RHI) in stable condition in MI patients. The
time point of measurement was in stable condition before discharge
of the MI admission or several months later. Because hs-CRP and RHI
are not normally distributed and someprevious study concerning endo-
thelial function and cardiovascular diseases expressed these values as
logarithmic transformation form, [19] we calculated the natural loga-
rithmic (Ln)-hs-CRP and RHI values for statistical analyses.
2.5. Statistical analysis
Since RHI values are not normally distributed, we calculated the nat-
ural logarithmic (Ln)-RHI values for statistical analyses.We conducted a
study on independent cases and controls with 1 control per case. Our
pilot data indicated that the probability of the simultaneous presence
of H. pylori infection and IL-1 polymorphisms among controls is 0.2. If
the true probability of that among cases is 0.4, we needed to study at
least 81 cases and 81 controls. Enrolled patients were matched by age
and sex using a propensity scoremethod. The Hardy–Weinberg equilib-
rium of alleles at individual loci was assessed using the chi-square test.
The odds ratio (OR) and 95% conﬁdence intervals (CI) were used to as-
sess the risk ofMI associatedwith the presence ofH. pylori infection and
IL-1 polymorphisms were estimated by using multivariate logistic
regression analysis, adjusted for the risk factors of MI. Estimates of
the C-statistic for the risk factors were calculated, and a comparison of
C-statistics was estimated after the addition of the simultaneous pres-
ence of H. pylori and IL-1 polymorphisms to the risk factors of indepen-
dent predictive values showed in the multivariate logistic regression
analysis. The incremental effect of adding the presence of H. pylori and
IL-1 polymorphisms to the conventional risk factors for predicting MI
was evaluated using the net reclassiﬁcation improvement (NRI), as pre-
viously described [20]. A P value b 0.05 was considered to denote the
presence of a statistically signiﬁcant difference. Statistical analyses
were performed using SPSS, version 22 (IBM Corp., Armonk, NY, USA).
3. Results
Table 1 shows the subjects' clinical characteristics. The cases had a
higher prevalence of diabetes (P=0.025), dyslipidemia (Pb 0.001), his-
tory of smoking (P b 0.001), medical history of previousMI (P= 0.014)Table 1
Clinical characteristics between the myocardial infarction (MI) and control group.
MI (n = 82) Control (n = 82) P value
Male (%) 55 (67.1) 55 (67.1) 1.0
Age, years 69.2 ± 9.5 68.3 ± 6.1 0.49
BMI, kg/m2 24.1 ± 3.5 23.4 ± 3.1 0.17
Diabetes (%) 31 (37.8) 17 (20.7) 0.025
Hypertension (%) 58 (70.7) 63 (76.8) 0.48
Dyslipidemia (%) 63 (76.8) 35 (42.7) b0.001
Smoking (%) 27 (32.9) 2 (2.4) b0.001
CKD (%) 25 (30.5) 15 (18.3) 0.1
Previous MI (%) 7 (8.5) 0 (0) 0.014
Previous stroke (%) 5 (6.1) 0 (0) 0.059
PAD (%) 6 (7.3) 0 (0) 0.028
ABI 1.09 ± 0.14 1.14 ± 0.08 0.016
baPWV 1605 ± 320 1659 ± 308 0.32
Ln-hs-CRP −3.1 ± 0.9 −3.1 ± 0.7 0.87
Ln-RHI 0.57 ± 0.2 0.65 ± 0.23 0.024
H. pylori IgG (%) 39 (47.6%) 26 (31.7%) 0.055
Abbreviations: MI, myocardial infarction; BMI, bodymass index; CKD, chronic kidney dis-
ease; PAD, peripheral arterial disease; ABI, ankle-brachial index; baPWV, brachial-ankle
pulse wave velocity; Ln-hs-CRP, natural logarithm of high-sensitivity C-reactive protein;
Ln-RHI, natural logarithm of reactive hyperemia index; H. pylori, Helicobacter pylori; IgG,
immunoglobulin.and peripheral arterial disease (P = 0.028). We found no signiﬁcant
differences between the cases and controls in the levels of natural loga-
rithm of hs-CRP (Ln-hs-CRP) (−3.1 ± 0.9 vs.−3.1 ± 0.7, respectively;
P = 0.87). The Ln-RHI was signiﬁcantly lower in the cases than in the
controls (0.57 ± 0.2 vs. 0.65 ± 0.23, respectively; P = 0.024).
All 164 subjects were successfully genotyped for the 2 loci (the IL-1
beta-511 genotype and IL-1RN alleles). Fig. 2 shows the results of
H. pylori seropositivity, IL-1 beta-511 genotype and IL-1RN alleles,
respectively. The prevalence of seropositivity to H. pylori IgG antibody
in the case and control groups was 47.6% and 31.7%, respectively
(P = 0.055) (Fig. 2A). The genotype frequencies of the IL-1 beta-511
C/C, C/T, and T/T were 26.8%, 46.3%, and 26.8%, respectively, in the
cases and were 32.9%, 45.1%, and 22%, respectively, in the controls
(P = 0.63) (Fig. 2B). The alleles of the IL-1 were in Hardy–Weinberg
equilibrium in the cases and controls (P = 0.54 and P = 0.41, respec-
tively). The distribution of the IL-1RN L/L, *2/L, *2/*2 genotype were
87.8%, 12.2%, and 0%, respectively, in the cases and were 91.5%, 8.5%,
and 0%, respectively, in the controls (P = 1.0) (Fig. 2C). The IL-1RN al-
leles were also in Hardy–Weinberg equilibrium in the cases and con-
trols (P = 0.52 and P = 0.68, respectively).
The rate of the simultaneous presence of H. pylori seropositivity
and IL-1 polymorphisms was 45.1% and 19.5% in the cases and controls
(P= 0.001) (Fig. 3). Subjects withH. pylori seropositivity and IL-1 poly-
morphisms showed signiﬁcantly higher serum levels of Ln-hs-CRP
in the cases and controls (−2.8 ± 1.0 vs. −3.4 ± 0.6, respectively;
P = 0.003 and −2.8 ± 0.9 vs. −3.2 ± 0.6, respectively; P = 0.02).
The Ln-RHIwas signiﬁcantly lower in patientswithH. pylori seropositiv-
ity and IL-1 polymorphisms than in other patients of the case and con-
trol groups (0.51 ± 0.13 vs. 0.61 ± 0.23, respectively; P = 0.039 and
0.47 ± 0.13 vs. 0.69 ± 0.23, respectively; P = 0.005) (Fig. 4).
Logistic regression analysis for MI revealed that the carriage of
H. pylori seropositivity and IL-1 polymorphisms was associated with a
signiﬁcantly high increased risk of MI (OR, 4.83; 95% CI: 1.99–11.7;
P b 0.001) after adjusting for diabetes, hypertension, dyslipidemia, obe-
sity, smoking, and chronic kidney disease (Table 2). The P value of the
Hosmer and Lemeshow test was 0.8. We estimated the C-statistic of
the risk factors for MI (C-statistic, 0.78; 95% CI: 0.71–0.84). The addition
of H. pylori seropositivity with IL-1 polymorphisms to the risk factors
resulted in a signiﬁcant increase in the C-statistics from 0.78 to 0.82
(P = 0.028) (Fig. 5). We reclassiﬁed the risk of the risk factors for MI,
and the net reclassiﬁcation improvement (NRI) was signiﬁcant with
the inclusion of H. pylori seropositivity and IL-1 polymorphisms
(P b 0.001) (Table 3).
4. Discussion
This is the ﬁrst study to reveal the association amongH. pylori infec-
tion, IL-1 polymorphisms, and the incidence of MI. The present study
has three important ﬁndings. First, H. pylori infection and IL-1 polymor-
phisms were foundmore signiﬁcantly in patients with MI than in those
without atherosclerotic diseases. Second, patients with H. pylori infec-
tion and IL-1 polymorphisms showed signiﬁcantly higher levels of hs-
CRP and signiﬁcantly lower levels of Ln-RHI. Third, the addition of
H. pylori infection with IL-1 polymorphisms to the previously described
risk factors improved the risk stratiﬁcation of the incidence of MI,
resulting in a substantial increase in the C-statistics and a signiﬁcant
NRI.
H. pylori infection is associated with clinical outcomes that range
from simple gastritis to more serious conditions such as peptic ulcer
and gastric neoplasia; however, the evidence of a relationship between
H. pylori infection and MI is controversial, [3,4] and H. pylori is not con-
sidered to have any detrimental effect on the classic coronary risk fac-
tors. [20] In contrast, some reports have shown that H. pylori infection
was signiﬁcantly associated with the incidence of MI in younger pa-
tients [21,22]. Therefore, H. pylori infection would be associated with
MI in patients with speciﬁed clinical characteristics. Detail mechanisms
Fig. 2. Results of the prevalence ofHelicobacter pylori and interleukin-1 polymorphisms between cases and controls. (A) Prevalence ofHelicobacter pylori. (B) Distribution of interleukin-1
beta-511 genotypes. (C) Distribution of interleukin-1RN alleles. MI, myocardial infarction; interleukin-1RN, interleukin-1 receptor antagonist.
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previous studies have demonstrated thatH. pylori infection is associated
with endothelial dysfunction [23] and that it might cause vulnerable
plaques. [24] Some of H. pylori strains possess cytotoxin-associated
gene-A (CagA), which is one of the major virulence factors of H. pylori,
and high prevalence of CagA-positive H. pylori strain has been reported
in Japan [25]. The anti-CagA antibodies react with antigens localized
within coronary atherosclerotic plaques leading to destabilization, [26]
and a past study showed a signiﬁcant association between CagA sero-
positivity and risk of cardiovascular diseases [24].Fig. 3. Prevalence of Helicobacter pyloriwith interleukin-1 polymorphisms between cases
and controls. MI, myocardial infarction.Previous reports have suggested the importance of IL-1 in H. pylori-
associated diseases and that IL-1 genetic polymorphisms are related to
gastric inﬂammation, atrophy, and gastric carcinogenesis [9]. Among
various genetic polymorphisms, C–T base transitions at position
−511 bp from the transcriptional start site and IL-1 RN *2 were report-
edly strongly associated with gastric inﬂammation and carcinogenesis,
and these genetic polymorphisms showed higher local levels of IL-1
beta than non-carriers. [9] Thus, the IL-1 polymorphisms could be im-
portant determinants of the inﬂammatory response in patients with
H. pylori infection, because cytokines such as IL-1 beta is important in
the inhibition of gastric acid secretion, [27] and the inhibition of gastric
acid enables larger colonization of H. pylori, [5] leading to continuous
chronic infection. To the best of our knowledge, there have not been
any reports that evaluate both the H. pylori infection and IL-1 polymor-
phisms in the increased risk of MI. At the present study, we hypothe-
sized that H. pylori infection and IL-1 polymorphisms are important in
chronic inﬂammation, pathogenesis of atherosclerosis, and incidence
of acute coronary events, and we investigated the H. pylori infection
and the genetic factors of IL-1 in cases and controls. As a result,
H. pylori-infected patients with IL-1 polymorphisms showed a signiﬁ-
cantly higher incidence of MI than the other subjects.
Atherosclerosis is an inﬂammatory disease, and inﬂammation has a
fundamental role in all the stages of atherosclerosis from initiation
through progression and, ﬁnally, in the thrombotic complications of
atherosclerosis.H. pylori is reported to be associatedwith increased con-
centrations of systemic markers of inﬂammation and inﬂammatory cy-
tokines [28]. Although there is some controversy regarding the effect of
cytokine polymorphismon the increased levels of serumcytokines, [8,9,
29] previous studies have stressed the role of cytokine polymorphisms
in determining the levels of inﬂammation associated with chronic
low-grade infections such as periodontal infections and Chlamydia
pneumoniae, leading to an increased risk of atherosclerosis, [30,31] so
the association between atherosclerosis and pathogen burden may be
modulated by cytokine polymorphisms. In the present study, patients
Fig. 4.Natural logarithm of reactive hyperemia index (Ln-RHI) between patients with Helicobacter pylori infection and interleukin (IL)-1 polymorphisms and the other patients. The bars
represent the average Ln-RHI. The T-bars indicate the standard deviations. MI, myocardial infarction.
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higher levels of hs-CRP and signiﬁcantly lower levels of Ln-RHI both in
MI and control groups. Therefore, there is a possibility that host cytokine
polymorphisms could enhance the inﬂammation from H. pylori infec-
tion and cause the development of vascular endothelial dysfunction
and atherosclerosis, resulting in the progression of coronary plaque
and acute coronary event. This low-grade systemic inﬂammation may
inﬂuence the initiation and progression of atherosclerosis and the inci-
dence of acute coronary event. Our study suggests that there will be
treatment options for eradicating the H. pylori pathogen or anti-
inﬂammatory agents to prevent adverse cardiovascular events; howev-
er, further studies are needed to conﬁrm our ﬁndings.4.1. Limitations
As a limitation of this study, it was performed at a single center, and
the number of this study subjects was relatively small, though sample
power analysis was done. We cannot deny that this background might
make our ﬁndings less convincing, and multicenter studies in much
larger subjects are needed in the future to conﬁrm our ﬁndings.Table 2
Logistic regression analysis for myocardial infarction.
Variable Univariate regression Multivariate regression
OR 95% CI P value OR 95% CI P value
H. pylori with IL-1
polymorphisms
3.39 1.69–6.82 0.001 4.83 1.99–11.7 b0.001
Diabetes 2.32 1.16–4.66 0.018 1.22 0.5–3.0 0.66
Hypertension 0.73 0.36–1.47 0.38 0.51 0.21–1.25 0.14
Dyslipidemia 4.45 2.27–8.74 b0.001 5.82 2.46–13.8 b0.001
Obesity 1.4 0.73–2.72 0.32 1.7 0.72–3.98 0.23
Smoking 19.6 4.48–86 b0.001 14.2 2.89–69.9 0.001
CKD 1.96 0.94–4.07 0.071 2.56 1.04–6.33 0.041
Abbreviations: OR, odds ratio; CI, conﬁdence interval;H. pylori,Helicobacter pylori; IL-1, in-
terleukin-1; CKD, chronic kidney disease.H. pylori infection is associated with multiple cofactors such as hygienic
environment and smoking habits, and H. pylori-associated diseases
might be partly explained by confounders. Also, the frequencies of IL-1
beta-511 genotype and IL-1RN *2 allele are different among ethnic pop-
ulations, and our resultsmay not be applicable all over theworld.More-
over, we did not measure the serum levels of inﬂammatory cytokines
such as IL-1 beta, IL-6, and tumor necrosis factor; thus, we did not dem-
onstrate that the systemic inﬂammation was induced by the elevation
of inﬂammatory cytokine levels.
5. Conclusions
The simultaneous presence of H. pylori infection and IL-1 polymor-
phisms showed higher levels of hs-CRP and lower levels of RHI, and
were signiﬁcantly correlated with the incidence of MI.Fig. 5. ROC curves for the model of conventional risk factors (age, male sex, obesity,
diabetes, hypertension, dyslipidemia, smoking, and chronic kidney disease) (A) and the
model after the addition of the simultaneous presence of Helicobacter pylori and
interleukin-1 polymorphisms (B).
Table 3
Reclassiﬁcation of risk factors for MI after the addition of H. pylori infection and IL-1 polymorphisms.
Reclassiﬁcation
RF + H. pylori with IL-1
Polymorphisms low risk
RF + H. pylori with IL-1
Polymorphisms intermediate risk
RF + H. pylori with IL-1
Polymorphisms high risk
Original risk category
Patients without cardiovascular events
RF low risk 0 0 0
RF Intermediate risk 29 15 1
RF High risk 0 24 13
Patients with cardiovascular events
RF low risk 0 0 0
RF intermediate risk 2 9 4
RF high risk 0 19 48
Abbreviations: MI, myocardial infarction; H. pylori, Helicobacter pylori; IL-1, interleukin-1; RF, risk factors (dyslipidemia, current smoking, and chronic kidney disease).
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